Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BHC Bausch Health Cos	$7.17 -1.4%	$6.68	$4.25 ▼ $9.85	$2.65B	0.41	2.67 million shs	1.64 million shs
GMTX Gemini Therapeutics	$59.95 +0.3%	$57.21	$1.16 ▼ $14.10	$2.60B	-0.12	189,291 shs	165,212 shs
IMVT Immunovant	$14.86 -2.1%	$16.35	$12.72 ▼ $34.47	$2.59B	0.66	1.45 million shs	362,095 shs
TBPH Theravance Biopharma	$13.95 +1.1%	$11.67	$7.88 ▼ $14.30	$702.28M	0.01	273,149 shs	285,539 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BHC Bausch Health Cos	+1.39%	-4.21%	+5.74%	+58.22%	+22.06%
GMTX Gemini Therapeutics	+0.63%	+2.76%	-1.36%	+32.50%	+20.22%
IMVT Immunovant	+0.66%	+2.43%	-9.43%	+1.95%	-52.14%
TBPH Theravance Biopharma	0.00%	+3.06%	+24.77%	+48.39%	+64.68%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BHC Bausch Health Cos	4.3375 of 5 stars	2.0	4.0	0.0	4.0	2.8	3.3	1.9
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IMVT Immunovant	2.8913 of 5 stars	4.4	2.0	0.0	0.0	2.6	1.7	0.0
TBPH Theravance Biopharma	2.085 of 5 stars	3.8	0.0	0.0	0.0	1.8	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BHC Bausch Health Cos	2.00	Hold	$9.00	25.61% Upside
GMTX Gemini Therapeutics	0.00	N/A	N/A	N/A
IMVT Immunovant	2.83	Moderate Buy	$35.20	136.32% Upside
TBPH Theravance Biopharma	3.50	Strong Buy	$21.33	53.41% Upside

Current Analyst Ratings Breakdown

Latest TBPH, BHC, IMVT, and GMTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	TBPH Theravance Biopharma	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/12/2025	IMVT Immunovant	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$40.00 ➝ $37.00
8/12/2025	IMVT Immunovant	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$33.00 ➝ $30.00
8/11/2025	IMVT Immunovant	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
7/28/2025	IMVT Immunovant	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$17.00 ➝ $18.00
7/10/2025	IMVT Immunovant	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold	$18.00
6/27/2025	TBPH Theravance Biopharma	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$24.00 ➝ $25.00
6/17/2025	TBPH Theravance Biopharma	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$24.00

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BHC Bausch Health Cos	$9.63B	0.28	$7.70 per share	0.93	$0.40 per share	17.91
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	$2.89 per share	N/A
IMVT Immunovant	N/A	N/A	N/A	N/A	$3.49 per share	N/A
TBPH Theravance Biopharma	$77.21M	9.07	N/A	N/A	$4.46 per share	3.12

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BHC Bausch Health Cos	-$46M	$0.26	27.54	1.54	N/A	0.99%	-852.36%	5.25%	10/29/2025 (Estimated)
GMTX Gemini Therapeutics	-$71.87M	-$1.00	N/A	N/A	N/A	N/A	-38.78%	-35.88%	N/A
IMVT Immunovant	-$413.84M	-$2.85	N/A	N/A	N/A	N/A	-80.99%	-72.23%	11/6/2025 (Estimated)
TBPH Theravance Biopharma	-$56.42M	$0.24	57.98	39.73	N/A	16.88%	6.93%	3.52%	11/11/2025 (Estimated)

Latest TBPH, BHC, IMVT, and GMTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q1 2026	IMVT Immunovant	-$0.69	-$0.60	+$0.09	-$0.71	N/A	N/A
7/30/2025	Q2 2025	BHC Bausch Health Cos	$0.97	$0.90	-$0.07	$0.40	$2.47 billion	$2.57 billion
5/29/2025	Q4 2025	IMVT Immunovant	-$0.72	-$0.64	+$0.08	-$0.64	N/A	$0.16 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BHC Bausch Health Cos	N/A	N/A	N/A	N/A	N/A
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A
IMVT Immunovant	N/A	N/A	N/A	N/A	N/A
TBPH Theravance Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BHC Bausch Health Cos	141.90	1.31	0.98
GMTX Gemini Therapeutics	N/A	71.49	71.49
IMVT Immunovant	N/A	12.32	12.32
TBPH Theravance Biopharma	N/A	6.70	6.70

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BHC Bausch Health Cos	78.65%
GMTX Gemini Therapeutics	75.42%
IMVT Immunovant	47.08%
TBPH Theravance Biopharma	99.10%

Insider Ownership

Company	Insider Ownership
BHC Bausch Health Cos	8.05%
GMTX Gemini Therapeutics	12.90%
IMVT Immunovant	1.80%
TBPH Theravance Biopharma	6.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BHC Bausch Health Cos	20,700	370.13 million	340.33 million	Optionable
GMTX Gemini Therapeutics	30	43.33 million	37.74 million	Not Optionable
IMVT Immunovant	120	174.32 million	171.18 million	Optionable
TBPH Theravance Biopharma	110	50.36 million	46.89 million	Optionable

TBPH, BHC, IMVT, and GMTX Headlines

Recent News About These Companies

Theravance Biopharma (NASDAQ:TBPH) Stock Price Crosses Above 50 Day Moving Average - Here's Why

August 28 at 4:41 AM | marketbeat.com

Theravance Biopharma, Inc.: Theravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic ...

August 25 at 10:35 PM | finanznachrichten.de

Theravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension due to Multiple ...

August 25 at 10:35 PM | finance.yahoo.com

Theravance Biopharma completes enrollment in CYPRESS study

August 25 at 12:32 PM | msn.com

Theravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension due to Multiple System Atrophy

August 25 at 6:00 AM | prnewswire.com

Theravance Biopharma Settles Patent Dispute with Cipla

August 20, 2025 | msn.com

Theravance Biopharma (NASDAQ:TBPH) Hits New 1-Year High - Here's What Happened

August 20, 2025 | marketbeat.com

Theravance Biopharma (NASDAQ:TBPH) Upgraded at Wall Street Zen

August 19, 2025 | americanbankingnews.com

Theravance Biopharma (NASDAQ:TBPH) Rating Increased to Strong-Buy at Wall Street Zen

August 17, 2025 | marketbeat.com

Theravance Biopharma (NASDAQ:TBPH) Stock Price Up 3.4% - Here's Why

August 16, 2025 | marketbeat.com

Theravance Biopharma (NASDAQ:TBPH) Sets New 1-Year High on Earnings Beat

August 14, 2025 | marketbeat.com

Theravance Biopharma (NASDAQ:TBPH) Announces Quarterly Earnings Results

August 14, 2025 | marketbeat.com

Theravance's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y

August 13, 2025 | zacks.com

Theravance Biopharma, Inc. (NASDAQ:TBPH) Q2 2025 Earnings Call Transcript

August 13, 2025 | msn.com

Theravance Biopharma Inc (TBPH) Q2 2025: Everything You Need To Know Ahead Of Earnings

August 13, 2025 | finance.yahoo.com

Theravance Biopharma reports Q2 EPS $1.08 with items, consensus (12c)

August 12, 2025 | msn.com

Theravance Biopharma, Inc. (TBPH) Q2 2025 Earnings Call Transcript

August 12, 2025 | seekingalpha.com

Theravance Biopharma (TBPH) Reports Q2 Loss, Tops Revenue Estimates

August 12, 2025 | zacks.com

Theravance Bio: Q2 Earnings Snapshot

August 12, 2025 | timesunion.comT

Theravance Biopharma, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 12, 2025 | prnewswire.com

Theravance Biopharma Q2 2025 Earnings Preview

August 11, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TBPH, BHC, IMVT, and GMTX Company Descriptions

Bausch Health Cos NYSE:BHC

$7.16 -0.11 (-1.44%)

Closing price 03:59 PM Eastern

Extended Trading

$7.16 -0.01 (-0.14%)

As of 04:04 PM Eastern

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Gemini Therapeutics NASDAQ:GMTX

$59.95 +0.17 (+0.28%)

As of 08/27/2025

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Immunovant NASDAQ:IMVT

$14.86 -0.33 (-2.14%)

Closing price 03:59 PM Eastern

Extended Trading

$14.82 -0.04 (-0.24%)

As of 04:04 PM Eastern

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Theravance Biopharma NASDAQ:TBPH

$13.94 +0.15 (+1.05%)

Closing price 03:59 PM Eastern

Extended Trading

$13.96 +0.02 (+0.14%)

As of 04:04 PM Eastern

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time